1 | superiority | 2,861 |
2 | non-inferiority | 1,819 |
3 | noninferiority | 1,597 |
4 | equivalence | 1,239 |
5 | bioequivalence | 966 |
6 | futility | 333 |
7 | equality | 131 |
8 | equivalency | 112 |
9 | inferiority | 95 |
10 | compass | 37 |
11 | efficacy/effectiveness | 35 |
12 | crash-2 | 34 |
13 | dose-proportionality | 23 |
14 | cleopatra | 22 |
15 | ma.17 | 18 |
16 | victor | 16 |
17 | dose-dependency | 15 |
18 | no-effect | 15 |
19 | zenith | 15 |
20 | irrelevance | 13 |
21 | dose-dependence | 12 |
22 | prepic | 12 |
23 | aldo-dhf | 10 |
24 | e4599 | 10 |
25 | non-superiority | 10 |
26 | nonequivalence | 10 |
27 | classic/occult | 9 |
28 | rt01 | 9 |
29 | nonindependence | 8 |
30 | subepithelium | 8 |
31 | bioequivalency | 7 |
32 | conko-001 | 7 |
33 | coronis | 7 |
34 | lth-1 | 7 |
35 | mpact | 7 |
36 | non-equivalence | 7 |
37 | nonsignificance | 7 |
38 | switchability | 7 |
39 | bmtp-11 | 6 |
40 | prowess-shock | 6 |
41 | sins | 6 |
42 | sirflox | 6 |
43 | 25ml | 5 |
44 | dexanabinol | 5 |
45 | euphrates | 5 |
46 | hasta | 5 |
47 | linq | 5 |
48 | mm-015 | 5 |
49 | noninferioritylequivalence | 5 |
50 | outcomes.one | 5 |
51 | phambili | 5 |
52 | prevent-hf | 5 |
53 | 'investigation | 4 |
54 | adjunctive-therapy | 4 |
55 | azcq-iptp | 4 |
56 | biopotency | 4 |
57 | chant | 4 |
58 | control-loop | 4 |
59 | non-resolution | 4 |
60 | otc-pet | 4 |
61 | stratall | 4 |
62 | zice | 4 |
63 | 28.5gy | 3 |
64 | acdc | 3 |
65 | andromeda | 3 |
66 | bv/ffn | 3 |
67 | dose-ratio | 3 |
68 | downtrend | 3 |
69 | flec-sl | 3 |
70 | fosidial | 3 |
71 | iona | 3 |
72 | nonfutility | 3 |
73 | nu-hit | 3 |
74 | pc-hiv | 3 |
75 | radiant-2 | 3 |
76 | results.three | 3 |
77 | urico-ictus | 3 |
78 | wham | 3 |
79 | 'mastery | 2 |
80 | abcsg-06 | 2 |
81 | ar'bicl2 | 2 |
82 | attila | 2 |
83 | avataxher | 2 |
84 | confucius | 2 |
85 | cpy+sal | 2 |
86 | delores | 2 |
87 | depiscan | 2 |
88 | equivalence/non-inferiority | 2 |
89 | exist-1 | 2 |
90 | femme | 2 |
91 | flaxpad | 2 |
92 | group-led | 2 |
93 | halt-hamburg | 2 |
94 | icaro-3 | 2 |
95 | impact2 | 2 |
96 | msquit | 2 |
97 | neozotac | 2 |
98 | nnt=29 | 2 |
99 | no-onset | 2 |
100 | noninvolvement | 2 |
101 | nonsuperiority | 2 |
102 | paola | 2 |
103 | parat | 2 |
104 | peducat | 2 |
105 | priscus | 2 |
106 | programme.a | 2 |
107 | prospere | 2 |
108 | reduce-aki | 2 |
109 | rossini | 2 |
110 | rtx-440 | 2 |
111 | save-hip3 | 2 |
112 | scope1 | 2 |
113 | submicrometre | 2 |
114 | t.cruzi | 2 |
115 | 'management | 1 |
116 | 'osteonecrosis | 1 |
117 | alpinus | 1 |
118 | amh- | 1 |
119 | arn077 | 1 |
120 | c=prospective | 1 |
121 | coinhibition | 1 |
122 | cost.seven | 1 |
123 | cotransfer | 1 |
124 | cpy+at | 1 |
125 | diarist | 1 |
126 | dose-relatedness | 1 |
127 | down-prescription | 1 |
128 | feature-selectivity | 1 |
129 | fluctuation/loss | 1 |
130 | galectin-3-immunoreactivity | 1 |
131 | hba1c≥8 | 1 |
132 | hg-sil | 1 |
133 | hyperdistensibility | 1 |
134 | inclusion.one | 1 |
135 | nano-polycrystals | 1 |
136 | non-surgically.neither | 1 |
137 | polyaetiology | 1 |
138 | r463c/rec | 1 |
139 | significance.twelve | 1 |
140 | subvectors | 1 |
141 | tests.four | 1 |
142 | tpm/smx | 1 |
1 | 'investigation | 4 |
2 | 'management | 1 |
3 | 'mastery | 2 |
4 | 'osteonecrosis | 1 |
5 | 25ml | 5 |
6 | 28.5gy | 3 |
7 | abcsg-06 | 2 |
8 | acdc | 3 |
9 | adjunctive-therapy | 4 |
10 | aldo-dhf | 10 |
11 | alpinus | 1 |
12 | amh- | 1 |
13 | andromeda | 3 |
14 | ar'bicl2 | 2 |
15 | arn077 | 1 |
16 | attila | 2 |
17 | avataxher | 2 |
18 | azcq-iptp | 4 |
19 | bioequivalence | 966 |
20 | bioequivalency | 7 |
21 | biopotency | 4 |
22 | bmtp-11 | 6 |
23 | bv/ffn | 3 |
24 | c=prospective | 1 |
25 | chant | 4 |
26 | classic/occult | 9 |
27 | cleopatra | 22 |
28 | coinhibition | 1 |
29 | compass | 37 |
30 | confucius | 2 |
31 | conko-001 | 7 |
32 | control-loop | 4 |
33 | coronis | 7 |
34 | cost.seven | 1 |
35 | cotransfer | 1 |
36 | cpy+at | 1 |
37 | cpy+sal | 2 |
38 | crash-2 | 34 |
39 | delores | 2 |
40 | depiscan | 2 |
41 | dexanabinol | 5 |
42 | diarist | 1 |
43 | dose-dependence | 12 |
44 | dose-dependency | 15 |
45 | dose-proportionality | 23 |
46 | dose-ratio | 3 |
47 | dose-relatedness | 1 |
48 | down-prescription | 1 |
49 | downtrend | 3 |
50 | e4599 | 10 |
51 | efficacy/effectiveness | 35 |
52 | equality | 131 |
53 | equivalence | 1,239 |
54 | equivalence/non-inferiority | 2 |
55 | equivalency | 112 |
56 | euphrates | 5 |
57 | exist-1 | 2 |
58 | feature-selectivity | 1 |
59 | femme | 2 |
60 | flaxpad | 2 |
61 | flec-sl | 3 |
62 | fluctuation/loss | 1 |
63 | fosidial | 3 |
64 | futility | 333 |
65 | galectin-3-immunoreactivity | 1 |
66 | group-led | 2 |
67 | halt-hamburg | 2 |
68 | hasta | 5 |
69 | hba1c≥8 | 1 |
70 | hg-sil | 1 |
71 | hyperdistensibility | 1 |
72 | icaro-3 | 2 |
73 | impact2 | 2 |
74 | inclusion.one | 1 |
75 | inferiority | 95 |
76 | iona | 3 |
77 | irrelevance | 13 |
78 | linq | 5 |
79 | lth-1 | 7 |
80 | ma.17 | 18 |
81 | mm-015 | 5 |
82 | mpact | 7 |
83 | msquit | 2 |
84 | nano-polycrystals | 1 |
85 | neozotac | 2 |
86 | nnt=29 | 2 |
87 | no-effect | 15 |
88 | no-onset | 2 |
89 | non-equivalence | 7 |
90 | non-inferiority | 1,819 |
91 | non-resolution | 4 |
92 | non-superiority | 10 |
93 | non-surgically.neither | 1 |
94 | nonequivalence | 10 |
95 | nonfutility | 3 |
96 | nonindependence | 8 |
97 | noninferiority | 1,597 |
98 | noninferioritylequivalence | 5 |
99 | noninvolvement | 2 |
100 | nonsignificance | 7 |
101 | nonsuperiority | 2 |
102 | nu-hit | 3 |
103 | otc-pet | 4 |
104 | outcomes.one | 5 |
105 | paola | 2 |
106 | parat | 2 |
107 | pc-hiv | 3 |
108 | peducat | 2 |
109 | phambili | 5 |
110 | polyaetiology | 1 |
111 | prepic | 12 |
112 | prevent-hf | 5 |
113 | priscus | 2 |
114 | programme.a | 2 |
115 | prospere | 2 |
116 | prowess-shock | 6 |
117 | r463c/rec | 1 |
118 | radiant-2 | 3 |
119 | reduce-aki | 2 |
120 | results.three | 3 |
121 | rossini | 2 |
122 | rt01 | 9 |
123 | rtx-440 | 2 |
124 | save-hip3 | 2 |
125 | scope1 | 2 |
126 | significance.twelve | 1 |
127 | sins | 6 |
128 | sirflox | 6 |
129 | stratall | 4 |
130 | subepithelium | 8 |
131 | submicrometre | 2 |
132 | subvectors | 1 |
133 | superiority | 2,861 |
134 | switchability | 7 |
135 | t.cruzi | 2 |
136 | tests.four | 1 |
137 | tpm/smx | 1 |
138 | urico-ictus | 3 |
139 | victor | 16 |
140 | wham | 3 |
141 | zenith | 15 |
142 | zice | 4 |
1 | amh- | 1 |
2 | rtx-440 | 2 |
3 | lth-1 | 7 |
4 | exist-1 | 2 |
5 | conko-001 | 7 |
6 | rt01 | 9 |
7 | bmtp-11 | 6 |
8 | scope1 | 2 |
9 | crash-2 | 34 |
10 | radiant-2 | 3 |
11 | ar'bicl2 | 2 |
12 | impact2 | 2 |
13 | icaro-3 | 2 |
14 | save-hip3 | 2 |
15 | mm-015 | 5 |
16 | abcsg-06 | 2 |
17 | ma.17 | 18 |
18 | arn077 | 1 |
19 | hba1c≥8 | 1 |
20 | nnt=29 | 2 |
21 | e4599 | 10 |
22 | programme.a | 2 |
23 | andromeda | 3 |
24 | attila | 2 |
25 | paola | 2 |
26 | iona | 3 |
27 | cleopatra | 22 |
28 | hasta | 5 |
29 | neozotac | 2 |
30 | acdc | 3 |
31 | r463c/rec | 1 |
32 | prepic | 12 |
33 | flaxpad | 2 |
34 | group-led | 2 |
35 | downtrend | 3 |
36 | zice | 4 |
37 | nonsignificance | 7 |
38 | irrelevance | 13 |
39 | dose-dependence | 12 |
40 | nonindependence | 8 |
41 | equivalence | 1,239 |
42 | non-equivalence | 7 |
43 | noninferioritylequivalence | 5 |
44 | nonequivalence | 10 |
45 | bioequivalence | 966 |
46 | results.three | 3 |
47 | femme | 2 |
48 | inclusion.one | 1 |
49 | outcomes.one | 5 |
50 | prospere | 2 |
51 | submicrometre | 2 |
52 | c=prospective | 1 |
53 | significance.twelve | 1 |
54 | prevent-hf | 5 |
55 | aldo-dhf | 10 |
56 | halt-hamburg | 2 |
57 | zenith | 15 |
58 | reduce-aki | 2 |
59 | phambili | 5 |
60 | rossini | 2 |
61 | t.cruzi | 2 |
62 | prowess-shock | 6 |
63 | fosidial | 3 |
64 | cpy+sal | 2 |
65 | hg-sil | 1 |
66 | stratall | 4 |
67 | 25ml | 5 |
68 | dexanabinol | 5 |
69 | flec-sl | 3 |
70 | wham | 3 |
71 | subepithelium | 8 |
72 | depiscan | 2 |
73 | cost.seven | 1 |
74 | bv/ffn | 3 |
75 | 'investigation | 4 |
76 | coinhibition | 1 |
77 | down-prescription | 1 |
78 | non-resolution | 4 |
79 | dose-ratio | 3 |
80 | control-loop | 4 |
81 | azcq-iptp | 4 |
82 | linq | 5 |
83 | cotransfer | 1 |
84 | non-surgically.neither | 1 |
85 | avataxher | 2 |
86 | victor | 16 |
87 | tests.four | 1 |
88 | delores | 2 |
89 | euphrates | 5 |
90 | coronis | 7 |
91 | 'osteonecrosis | 1 |
92 | nano-polycrystals | 1 |
93 | sins | 6 |
94 | subvectors | 1 |
95 | compass | 37 |
96 | dose-relatedness | 1 |
97 | efficacy/effectiveness | 35 |
98 | fluctuation/loss | 1 |
99 | priscus | 2 |
100 | confucius | 2 |
101 | alpinus | 1 |
102 | urico-ictus | 3 |
103 | cpy+at | 1 |
104 | peducat | 2 |
105 | parat | 2 |
106 | mpact | 7 |
107 | no-effect | 15 |
108 | otc-pet | 4 |
109 | no-onset | 2 |
110 | nu-hit | 3 |
111 | msquit | 2 |
112 | classic/occult | 9 |
113 | chant | 4 |
114 | 'management | 1 |
115 | noninvolvement | 2 |
116 | diarist | 1 |
117 | pc-hiv | 3 |
118 | tpm/smx | 1 |
119 | sirflox | 6 |
120 | dose-dependency | 15 |
121 | equivalency | 112 |
122 | bioequivalency | 7 |
123 | biopotency | 4 |
124 | 28.5gy | 3 |
125 | polyaetiology | 1 |
126 | adjunctive-therapy | 4 |
127 | 'mastery | 2 |
128 | dose-proportionality | 23 |
129 | equality | 131 |
130 | switchability | 7 |
131 | hyperdistensibility | 1 |
132 | futility | 333 |
133 | nonfutility | 3 |
134 | inferiority | 95 |
135 | non-inferiority | 1,819 |
136 | equivalence/non-inferiority | 2 |
137 | noninferiority | 1,597 |
138 | superiority | 2,861 |
139 | non-superiority | 10 |
140 | nonsuperiority | 2 |
141 | galectin-3-immunoreactivity | 1 |
142 | feature-selectivity | 1 |